全球与中国司库奇尤单抗注射液市场运营态势及前景预测研究报告2024-2030年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 2.1 全球司库奇尤单抗注射液总体市场规模：2023 VS 2030 ...
英矽智能发布了ISM001-055药物临床试验结果。该药物由生成式人工智能设计，旨在治疗慢性肺病特发性肺纤维化（IPF）。美国约有10万IPF患者，随着病情发展，患者呼吸会愈发困难。
2003年，瑞士制药商诺华（Novartis）将新英格兰糖果威 ... 我们保留追究相应责任的权利 部分图片难以找到原始出处，故文中未加以标注，如若侵犯 ...
Hosted on MSN26d
减肥增肌研究与激活素药物：下一个重磅呼之欲出？礼来和来凯医药(2105.HK)值得关注比利时蓝牛 图片来源|网络 肌肉生长抑制素 ... 2005年，时任诺华生物医学研究所(Novartis Institutes for BioMedical Research)所长菲什曼(Mark Fishman)在《自然 ...
Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback